<?xml version='1.0' encoding='utf-8'?>
<document id="21252289"><sentence text="Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins."><entity charOffset="16-24" id="DDI-PubMed.21252289.s1.e0" text="tyrosine" /></sentence><sentence text="The drug-drug interaction (DDI) potential of tyrosine kinase inhibitors (TKI) as interacting drugs via transporter inhibition has not been fully assessed"><entity charOffset="45-53" id="DDI-PubMed.21252289.s2.e0" text="tyrosine" /></sentence><sentence text=" Here, we estimated the half maximal inhibitory concentration (IC(50)) values for 8 small-molecule TKIs (imatinib, dasatinib, nilotinib, gefitinib, erlotinib, sunitinib, lapatinib, and sorafenib) on [(14)C]metformin transport by human organic cation transporters (OCT), OCT1, OCT2, and OCT3, and multidrug and toxic compound extrusion (MATE) proteins, MATE1 and MATE2-K, using human embryonic kidney cells stably expressing these transporters"><entity charOffset="105-113" id="DDI-PubMed.21252289.s3.e0" text="imatinib" /><entity charOffset="115-124" id="DDI-PubMed.21252289.s3.e1" text="dasatinib" /><entity charOffset="126-135" id="DDI-PubMed.21252289.s3.e2" text="nilotinib" /><entity charOffset="137-146" id="DDI-PubMed.21252289.s3.e3" text="gefitinib" /><entity charOffset="148-157" id="DDI-PubMed.21252289.s3.e4" text="erlotinib" /><entity charOffset="159-168" id="DDI-PubMed.21252289.s3.e5" text="sunitinib" /><entity charOffset="170-179" id="DDI-PubMed.21252289.s3.e6" text="lapatinib" /><entity charOffset="185-194" id="DDI-PubMed.21252289.s3.e7" text="sorafenib" /><entity charOffset="199-215" id="DDI-PubMed.21252289.s3.e8" text="[(14)C]metformin" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e0" e2="DDI-PubMed.21252289.s3.e0" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e0" e2="DDI-PubMed.21252289.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e0" e2="DDI-PubMed.21252289.s3.e2" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e0" e2="DDI-PubMed.21252289.s3.e3" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e0" e2="DDI-PubMed.21252289.s3.e4" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e0" e2="DDI-PubMed.21252289.s3.e5" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e0" e2="DDI-PubMed.21252289.s3.e6" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e0" e2="DDI-PubMed.21252289.s3.e7" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e0" e2="DDI-PubMed.21252289.s3.e8" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e1" e2="DDI-PubMed.21252289.s3.e1" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e1" e2="DDI-PubMed.21252289.s3.e2" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e1" e2="DDI-PubMed.21252289.s3.e3" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e1" e2="DDI-PubMed.21252289.s3.e4" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e1" e2="DDI-PubMed.21252289.s3.e5" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e1" e2="DDI-PubMed.21252289.s3.e6" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e1" e2="DDI-PubMed.21252289.s3.e7" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e1" e2="DDI-PubMed.21252289.s3.e8" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e2" e2="DDI-PubMed.21252289.s3.e2" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e2" e2="DDI-PubMed.21252289.s3.e3" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e2" e2="DDI-PubMed.21252289.s3.e4" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e2" e2="DDI-PubMed.21252289.s3.e5" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e2" e2="DDI-PubMed.21252289.s3.e6" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e2" e2="DDI-PubMed.21252289.s3.e7" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e2" e2="DDI-PubMed.21252289.s3.e8" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e3" e2="DDI-PubMed.21252289.s3.e3" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e3" e2="DDI-PubMed.21252289.s3.e4" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e3" e2="DDI-PubMed.21252289.s3.e5" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e3" e2="DDI-PubMed.21252289.s3.e6" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e3" e2="DDI-PubMed.21252289.s3.e7" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e3" e2="DDI-PubMed.21252289.s3.e8" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e4" e2="DDI-PubMed.21252289.s3.e4" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e4" e2="DDI-PubMed.21252289.s3.e5" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e4" e2="DDI-PubMed.21252289.s3.e6" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e4" e2="DDI-PubMed.21252289.s3.e7" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e4" e2="DDI-PubMed.21252289.s3.e8" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e5" e2="DDI-PubMed.21252289.s3.e5" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e5" e2="DDI-PubMed.21252289.s3.e6" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e5" e2="DDI-PubMed.21252289.s3.e7" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e5" e2="DDI-PubMed.21252289.s3.e8" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e6" e2="DDI-PubMed.21252289.s3.e6" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e6" e2="DDI-PubMed.21252289.s3.e7" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e6" e2="DDI-PubMed.21252289.s3.e8" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e7" e2="DDI-PubMed.21252289.s3.e7" /><pair ddi="false" e1="DDI-PubMed.21252289.s3.e7" e2="DDI-PubMed.21252289.s3.e8" /></sentence><sentence text=" We then compared the estimated IC(50) values to the maximum clinical concentrations of unbound TKIs in plasma (unbound C(max,sys,p))"><entity charOffset="32-38" id="DDI-PubMed.21252289.s4.e0" text="IC(50)" /></sentence><sentence text=" Results showed that imatinib, nilotinib, gefitinib, and erlotinib exerted selectively potent inhibitory effects, with unbound C(max,sys,p)/IC(50) values â‰¥0"><entity charOffset="21-29" id="DDI-PubMed.21252289.s5.e0" text="imatinib" /><entity charOffset="31-40" id="DDI-PubMed.21252289.s5.e1" text="nilotinib" /><entity charOffset="42-51" id="DDI-PubMed.21252289.s5.e2" text="gefitinib" /><entity charOffset="57-66" id="DDI-PubMed.21252289.s5.e3" text="erlotinib" /><pair ddi="false" e1="DDI-PubMed.21252289.s5.e0" e2="DDI-PubMed.21252289.s5.e0" /><pair ddi="false" e1="DDI-PubMed.21252289.s5.e0" e2="DDI-PubMed.21252289.s5.e1" /><pair ddi="false" e1="DDI-PubMed.21252289.s5.e0" e2="DDI-PubMed.21252289.s5.e2" /><pair ddi="false" e1="DDI-PubMed.21252289.s5.e0" e2="DDI-PubMed.21252289.s5.e3" /><pair ddi="false" e1="DDI-PubMed.21252289.s5.e1" e2="DDI-PubMed.21252289.s5.e1" /><pair ddi="false" e1="DDI-PubMed.21252289.s5.e1" e2="DDI-PubMed.21252289.s5.e2" /><pair ddi="false" e1="DDI-PubMed.21252289.s5.e1" e2="DDI-PubMed.21252289.s5.e3" /><pair ddi="false" e1="DDI-PubMed.21252289.s5.e2" e2="DDI-PubMed.21252289.s5.e2" /><pair ddi="false" e1="DDI-PubMed.21252289.s5.e2" e2="DDI-PubMed.21252289.s5.e3" /></sentence><sentence text="1, on MATE1, OCT3, MATE2-K, and OCT1, respectively" /><sentence text=" In comparison to the common form of OCT1, the OCT1 polymorphism, M420del, was more sensitive to drug inhibition by erlotinib"><entity charOffset="116-125" id="DDI-PubMed.21252289.s7.e0" text="erlotinib" /></sentence><sentence text=" Major metabolites of several TKIs showed IC(50) values similar to those for unchanged TKIs" /><sentence text=" Taken together, these findings suggest the potential of clinical transporter-mediated DDIs between specific TKIs and OCTs and MATEs, which may affect the disposition, efficacy, and toxicity of metformin and other drugs that are substrates of these transporters"><entity charOffset="194-203" id="DDI-PubMed.21252289.s9.e0" text="metformin" /></sentence><sentence text=" The study provides the basis for further clinical DDI studies with TKIs" /><sentence text="" /></document>